The impact of hormones in autoimmune cutaneous diseases
Introduction Dermatomyositis, systemic and cutaneous lupus erythematosus have a significantly higher prevalence in women than men, emphasizing the relevance of exploring the relationship between sex hormones and autoimmune skin diseases. This review analyzes the interplay between sex hormones and th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2312241 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064098167881728 |
|---|---|
| author | Lais Lopes Almeida Gomes Adrienne J. Werth Preethi Thomas Victoria P. Werth |
| author_facet | Lais Lopes Almeida Gomes Adrienne J. Werth Preethi Thomas Victoria P. Werth |
| author_sort | Lais Lopes Almeida Gomes |
| collection | DOAJ |
| description | Introduction Dermatomyositis, systemic and cutaneous lupus erythematosus have a significantly higher prevalence in women than men, emphasizing the relevance of exploring the relationship between sex hormones and autoimmune skin diseases. This review analyzes the interplay between sex hormones and these two skin diseases.Materials and methods We performed an extensive literature search using the PubMed database from July to August 2023. Search terms included ‘contraceptives’, ‘pregnancy’, ‘hormone replacement’, ‘tamoxifen’, and ‘aromatase inhibitors’.Results and Discussion This comprehensive literature review shows that there remains considerable debate regarding the use of hormonal contraceptives and hormonal replacement therapy in individuals with autoimmune skin conditions. Nonetheless, it is well established that their use is contraindicated in patients with antiphospholipid syndrome or when antiphospholipid antibodies are positive. Individuals experiencing disease flares and uncontrolled symptoms should also avoid these interventions. Pregnancy planning should be timed to coincide with well-managed disease states to minimize obstetric and neonatal complications. Hormonal breast cancer treatment requires close skin monitoring.Conclusion Pregnancy, menopause, contraceptive use, hormone replacement therapy, and breast cancer treatment drugs result in substantial shifts in hormone levels. Additionally, hormone levels are altered by aromatase inhibitors and anti-estrogen medications. These fluctuations can modulate mechanisms influencing autoimmune skin abnormalities. |
| format | Article |
| id | doaj-art-2fa1a111add94225bbb1a88cec9e8564 |
| institution | DOAJ |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-2fa1a111add94225bbb1a88cec9e85642025-08-20T02:49:23ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2312241The impact of hormones in autoimmune cutaneous diseasesLais Lopes Almeida Gomes0Adrienne J. Werth1Preethi Thomas2Victoria P. Werth3Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USADepartment of Urogynecology, Hartford Healthcare, Hartford, CT, USADepartment of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, USACorporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USAIntroduction Dermatomyositis, systemic and cutaneous lupus erythematosus have a significantly higher prevalence in women than men, emphasizing the relevance of exploring the relationship between sex hormones and autoimmune skin diseases. This review analyzes the interplay between sex hormones and these two skin diseases.Materials and methods We performed an extensive literature search using the PubMed database from July to August 2023. Search terms included ‘contraceptives’, ‘pregnancy’, ‘hormone replacement’, ‘tamoxifen’, and ‘aromatase inhibitors’.Results and Discussion This comprehensive literature review shows that there remains considerable debate regarding the use of hormonal contraceptives and hormonal replacement therapy in individuals with autoimmune skin conditions. Nonetheless, it is well established that their use is contraindicated in patients with antiphospholipid syndrome or when antiphospholipid antibodies are positive. Individuals experiencing disease flares and uncontrolled symptoms should also avoid these interventions. Pregnancy planning should be timed to coincide with well-managed disease states to minimize obstetric and neonatal complications. Hormonal breast cancer treatment requires close skin monitoring.Conclusion Pregnancy, menopause, contraceptive use, hormone replacement therapy, and breast cancer treatment drugs result in substantial shifts in hormone levels. Additionally, hormone levels are altered by aromatase inhibitors and anti-estrogen medications. These fluctuations can modulate mechanisms influencing autoimmune skin abnormalities.https://www.tandfonline.com/doi/10.1080/09546634.2024.2312241Hormone replacement therapypregnancyestrogen modulatorsoral contraceptivescutaneous lupusdermatomyositis |
| spellingShingle | Lais Lopes Almeida Gomes Adrienne J. Werth Preethi Thomas Victoria P. Werth The impact of hormones in autoimmune cutaneous diseases Journal of Dermatological Treatment Hormone replacement therapy pregnancy estrogen modulators oral contraceptives cutaneous lupus dermatomyositis |
| title | The impact of hormones in autoimmune cutaneous diseases |
| title_full | The impact of hormones in autoimmune cutaneous diseases |
| title_fullStr | The impact of hormones in autoimmune cutaneous diseases |
| title_full_unstemmed | The impact of hormones in autoimmune cutaneous diseases |
| title_short | The impact of hormones in autoimmune cutaneous diseases |
| title_sort | impact of hormones in autoimmune cutaneous diseases |
| topic | Hormone replacement therapy pregnancy estrogen modulators oral contraceptives cutaneous lupus dermatomyositis |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2312241 |
| work_keys_str_mv | AT laislopesalmeidagomes theimpactofhormonesinautoimmunecutaneousdiseases AT adriennejwerth theimpactofhormonesinautoimmunecutaneousdiseases AT preethithomas theimpactofhormonesinautoimmunecutaneousdiseases AT victoriapwerth theimpactofhormonesinautoimmunecutaneousdiseases AT laislopesalmeidagomes impactofhormonesinautoimmunecutaneousdiseases AT adriennejwerth impactofhormonesinautoimmunecutaneousdiseases AT preethithomas impactofhormonesinautoimmunecutaneousdiseases AT victoriapwerth impactofhormonesinautoimmunecutaneousdiseases |